Vulvar Carcinoma – Comprehensive Medical Guide

Overview

Vulvar carcinoma (also called vulvar cancer) is a malignant tumor that arises from the skin or the mucous membranes of the vulva, the external part of the female genitalia. The most common type is squamous cell carcinoma, which develops from the squamous cells that line the surface of the vulva. Less common histologies include melanoma, adenocarcinoma, basal cell carcinoma, and sarcoma.

• Who it affects: Primarily women over the age of 60, but it can occur at any age, including in adolescents with certain pre‑cancerous conditions.
• Prevalence: In the United States, vulvar cancer accounts for about 5% of all female genital tract cancers. The CDC reports approximately 6,300 new cases and 1,300 deaths annually in the U.S. (2023 data). Worldwide incidence varies, ranging from 1 to 2 cases per 100,000 women, with higher rates in regions where human papillomavirus (HPV) infection is common.
• Prognosis: When detected early (stage I), the 5‑year survival rate exceeds 80%, but drops to 30–40% for advanced disease (stage III–IV) ¹.

Symptoms

Vulvar carcinoma may develop slowly and can be mistaken for benign conditions such as eczema or Bartholin’s cyst. Any persistent change that does not resolve within 2–3 weeks warrants evaluation.

Common signs and symptoms

• Visible lesion or lump: A raised, ulcerated, or firm nodule on the labia majora, labia minora, clitoral hood, or vestibule. It may be pink, white, or pigmented.
• Itching (pruritus): Persistent or worsening itching localized to the vulva.
• Pain or burning: Discomfort that can be constant or provoked by sitting, sexual activity, or clothing friction.
• Bleeding or discharge: Unexplained vaginal or vulvar bleeding, especially after intercourse, or a watery/serous discharge from a lesion.
• Skin changes: Redness, scaling, thickening (hyperkeratosis), or a rash that does not improve with standard topical therapy.
• Swelling or lymphadenopathy: Enlargement of the groin (inguinal) lymph nodes, which may be painless or tender.
• Urinary or bowel symptoms: Rarely, a large tumor can compress the urethra or rectum, causing difficulty urinating or constipation.

Causes and Risk Factors

Vulvar carcinoma is multifactorial. Understanding the underlying mechanisms helps identify individuals who may benefit from closer surveillance.

Human papillomavirus (HPV) infection

• High‑risk HPV types 16 and 18 are linked to ~30% of vulvar cancers, especially in younger women (<50 years) ².
• HPV‑related lesions often arise from vulvar intraepithelial neoplasia (VIN) grade 2/3.

Lichen sclerosus

• A chronic inflammatory skin condition that predisposes to VIN grade 1 and ultimately to non‑HPV‑related squamous cell carcinoma, typically in older women.

Other risk factors

• Age > 60 years (median age at diagnosis ~68 y).
• Smoking – doubles the risk of vulvar cancer and hinders immune clearance of HPV.
• Immunosuppression – organ transplant recipients, HIV infection, or prolonged corticosteroid use.
• Previous genital cancers – women with a history of cervical, vaginal, or anal cancer have a higher incidence.
• Chronic vulvar irritation – from poor hygiene, dermatitis, or repeated infections.
• Family history of HPV‑related cancers may suggest a shared susceptibility.

Diagnosis

Early diagnosis relies on a high index of suspicion and a systematic evaluation.

Clinical examination

• Visual inspection and systematic palpation of the vulva and both inguinal regions.
• Documentation of size, color, ulceration, and fixation of any lesion.

Biopsy

• Punch or incisional biopsy: The gold standard for confirming malignancy. Multiple biopsies may be needed if the lesion is heterogeneous.
• Pathology reports include tumor type, grade, depth of invasion, and presence of HPV DNA (via PCR or in‑situ hybridization).

Imaging studies

• Pelvic MRI: Provides detailed delineation of tumor extent and involvement of adjacent structures.
• CT scan of the abdomen/pelvis: Helpful for evaluating distant metastasis.
• PET‑CT: Detects metabolically active lymph nodes and distant disease.
• Ultrasound of inguinal lymph nodes: First‑line for assessing nodal enlargement.

Staging

The International Federation of Gynecology and Obstetrics (FIGO) 2023 staging system is used. Stages range from IA (microinvasive, <2 mm depth) to IV (regional or distant spread).

Treatment Options

Treatment is individualized based on stage, tumor size, location, patient comorbidities, and preferences. Multidisciplinary care (gynecologic oncology, radiation oncology, pathology, radiology, and supportive services) yields the best outcomes.

Surgical Management

• Wide local excision (WLE): Preferred for early‑stage, small (<2 cm) lesions. Margins of ≥1 cm are aimed for.
• Radical local excision: For larger lesions where WLE would compromise function.
• Vulvectomy: Partial, total, or radical vulvectomy for extensive disease.
• Inguinal lymphadenectomy: Ipsilateral or bilateral removal of superficial and deep inguinal nodes, indicated for tumors >1 cm depth or clinically positive nodes.
• Sentinel lymph node biopsy (SLNB): For tumors ≤4 cm with <1 mm depth of invasion; reduces morbidity compared with full node dissection.

Radiation Therapy

• External beam radiation (EBRT) to the pelvis and inguinal regions as primary treatment for medically inoperable patients or as adjuvant therapy after surgery with high‑risk features.
• brachytherapy can be used for selected small lesions.

Systemic Therapy

• Chemotherapy: Platinum‑based regimens (cisplatin or carboplatin) combined with 5‑fluorouracil (5‑FU) or taxanes are standard for locally advanced or metastatic disease.
• Targeted therapy: EGFR inhibitors (cetuximab) have shown activity in refractory squamous cell carcinoma.
• Immunotherapy: Pembrolizumab (PD‑1 inhibitor) is FDA‑approved for PD‑L1‑positive, recurrent, or metastatic vulvar SCC after chemotherapy failure (based on KEYNOTE‑158 trial).
• Clinical trials are ongoing for HPV‑directed vaccines and novel checkpoint inhibitors.

Lifestyle & Supportive Measures

• Smoking cessation improves wound healing and overall outcomes.
• Nutrition counseling to maintain weight and immune function during treatment.
• Pain management – NSAIDs, opioids, or neuropathic agents as needed.
• Lymphedema prevention – compression garments and physiotherapy after node dissection.

Living with Vulvar Carcinoma

Adjusting to diagnosis and treatment can be challenging. Practical steps help maintain quality of life.

Physical care

• Hygiene: Gentle cleansing with warm water; avoid scented soaps, douches, or harsh wipes.
• Skin protection: Apply barrier ointments (e.g., zinc oxide) to prevent irritation from incontinence or moisture.
• Sexual health: Use water‑based lubricants; discuss pelvic floor physical therapy if pain persists.
• Lymphedema: Perform daily range‑of‑motion exercises; wear fitted compression stockings if recommended.

Emotional & psychosocial support

• Join support groups (e.g., CancerCare, local vulvar cancer networks).
• Consider counseling or psychotherapy to address anxiety, body‑image concerns, and relationship changes.
• Engage a sexual health specialist if intimacy issues arise.

Follow‑up care

• First 2 years: Visit every 3–4 months for physical exam and symptom review; imaging only if clinically indicated.
• Years 3‑5: Visits every 6 months; annual pelvic exam thereafter.
• Long‑term: Monitor for secondary cancers (cervical, vaginal, anal) and for late effects of radiation (e.g., fibrosis).

Prevention

While not all cases are preventable, several measures significantly lower risk.

• HPV vaccination: The 9‑valent vaccine (Gardasil 9) protects against HPV 16/18 and other oncogenic types. CDC recommends routine vaccination for females ages 9‑26 and shared decision‑making up to age 45.
• Smoking cessation: Reduces both the risk of HPV persistence and overall cancer risk.
• Safe sexual practices: Consistent condom use reduces HPV transmission.
• Regular gynecologic exams: Early detection of VIN or lichen sclerosus enables treatment before malignant transformation.
• Management of lichen sclerosus: High‑potency topical steroids (clobetasol propionate 0.05 %) applied daily for 4‑6 weeks, then tapered, can prevent progression.

Complications

If untreated or inadequately managed, vulvar carcinoma can lead to serious health issues.

• Local invasion: Extension to the urethra, vagina, anus, or pelvic sidewall causing urinary, fecal, or sexual dysfunction.
• Inguinal lymph node metastasis: Leads to regional spread and higher mortality.
• Lymphedema: Chronic swelling of the lower limbs after node dissection.
• Infection and ulceration: Open malignant lesions can become secondarily infected.
• Pain and decreased quality of life: Persistent neuropathic or nociceptive pain.
• Psychological impact: Depression, anxiety, and sexual identity concerns.
• Secondary malignancies: Radiation can increase the risk of sarcoma or other skin cancers in the treated field.

When to Seek Emergency Care

References

1. Mayo Clinic. “Vulvar cancer.” 2023. https://www.mayoclinic.org
2. CDC. “Human papillomavirus (HPV) and Cancer.” 2022. https://www.cdc.gov
3. National Cancer Institute. “Vulvar Cancer Treatment (PDQ®)–Health Professional Version.” 2023. https://www.cancer.gov
4. World Health Organization. “HPV and Cervical Cancer.” 2022. https://www.who.int
5. Cleveland Clinic. “Vulvar Cancer.” 2023. https://my.clevelandclinic.org
6. Barthold JS, et al. “Sentinel lymph node biopsy in vulvar cancer: long‑term outcomes.” *Gynecologic Oncology*, 2021; 162(1):165‑172.